George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
|Articles|September 16, 2008
- March15 2004
- Volume 11
- Issue 5
LTC Insurance for You?
Author(s)Michael Sheehan
Advertisement
Consumer Reports(CR)
CR
Some insurers are pushing long-term-care(LTC) insurance to prospects in their40s, which is a bad idea, according to arecent study from . The pitch is that premiums growlarger the longer you wait, but the report notes that many people wouldhave trouble paying hefty premiums forcoverage they may not need for years.Plus, there's no guarantee that the companythat issues the policy will bearound to pay the nursing home billsthat come due several years in thefuture. Other financial advisors thinkLTC insurance is a good idea, but suggestwaiting until you are around age 60to buy a policy. This helps balance thehigher premiums against the increasedrisk that you will need LTC.
Articles in this issue
about 18 years ago
Benefit from Social Security Knowledgeabout 18 years ago
Secure the Future with Trust Strategiesabout 18 years ago
Choose the Attorney Who's Right for Youabout 18 years ago
Decide on Your Ideal Financial Plannerabout 18 years ago
Is Your Advisor Walking All Over You?about 18 years ago
Arm Yourself if You Are Incorporatedabout 18 years ago
Hello, My Name Is Doctor and I'm in Debtabout 18 years ago
Repel Potential Plaintiffs with Trustsabout 18 years ago
Medicare Cuts Still Loomabout 18 years ago
Medicare BonusesAdvertisement
Related to this article
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.
Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.
Advertisement
Advertisement
Trending on HCPLive
1
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
2
FAQ: What the Expanded Marstacimab Approval Means for Hemophilia A, B
3
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5